AHA26: Lilly’s Foundayo benefits beyond weight loss in Phase III sleep apnoea win
Eli Lilly’s oral weight loss drug, Foundayo (orforglipron), has shown benefit as a treatment for adults with moderate-to-severe obstructive sleep…
News
Faeth’s combo posts mid-stage refractory endometrial cancer win
BMS’s Camzyos shows continued benefit in paediatric oHCM at 56 weeks
OncoC4 announces positive Phase I/II findings for cesalatamig in NSCLC
WHO adds two more Ebola vaccines to clinical trial
Gilead seeks wider use for Livdelzi on Phase III liver disease success
Amgen’s Repatha reduces heart attack risk in real-world study
Mondego Bio begins Phase Ia trial of oral MB‑388
